Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

This study is testing whether continuing treatment with sacituzumab govitecan (an antibody-drug combination, SG) plus immunotherapy (atezolizumab or durvalumab) as ongoing maintenance therapy can help keep extensive-stage small-cell lung cancer under control after initial chemotherapy and immunotherapy. **You may be eligible if...** - You are 18 or older - You have confirmed extensive-stage small-cell lung cancer - You completed at least 4 cycles of platinum/etoposide chemotherapy plus 2–3 cycles of immunotherapy (atezolizumab or durvalumab) with no signs of progression - Your cancer is stable or responding on the most recent scan - You are in reasonably good health (ECOG 0–2) with adequate organ function - Stable brain metastases are allowed **You may NOT be eligible if...** - Your cancer has spread to the lining of the brain (leptomeningeal disease) - You have severe kidney or end-stage liver disease - You had a recent diagnosis of heart failure or heart attack (within 3 months) - Immunotherapy was stopped due to serious immune-related side effects - You have active inflammatory bowel disease Talk to your doctor to see if this trial is right for you.